TY - JOUR
T1 - HMG-CoA reductase inhibitor augments the serum total cholesterol-lowering effect of human adipose tissue-derived multilineage progenitor cells in hyperlipidemic homozygous Watanabe rabbits
AU - Saga, Ayami
AU - Okura, Hanayuki
AU - Soeda, Mayumi
AU - Tani, Junko
AU - Fumimoto, Yuichi
AU - Komoda, Hiroshi
AU - Moriyama, Mariko
AU - Moriyama, Hiroyuki
AU - Yamashita, Shizuya
AU - Ichinose, Akihiro
AU - Daimon, Takashi
AU - Hayakawa, Takao
AU - Matsuyama, Akifumi
N1 - Funding Information:
This study was supported in part by the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NIBIO), and Kobe Translational Research Cluster , the Knowledge Cluster Initiative , Ministry of Education, Culture, Sports, Science and Technology (MEXT).
PY - 2011/8/19
Y1 - 2011/8/19
N2 - Familial hypercholesterolemia (FH) is an autosomal codominant disease characterized by high concentrations of proatherogenic lipoproteins secondary to deficiency in low-density lipoprotein (LDL) receptor. We reported recently the use of in situ stem cell therapy of human adipose tissue-derived multilineage progenitor cells (hADMPCs) in lowering serum total cholesterol in the homozygous Watanabe heritable hyperlipidemic (WHHL) rabbits, an animal model of homozygous FH. Here we demonstrate that pravastatin, an HMG-CoA reductase inhibitor, augmented the cholesterol-lowering effect of transplanted hADMPCs and enhanced LDL clearance in homozygous WHHL rabbit. The results suggest the potential beneficial effects of in situ stem cell therapy in concert with appropriately selected pharmaceutical agents, in regenerative medicine.
AB - Familial hypercholesterolemia (FH) is an autosomal codominant disease characterized by high concentrations of proatherogenic lipoproteins secondary to deficiency in low-density lipoprotein (LDL) receptor. We reported recently the use of in situ stem cell therapy of human adipose tissue-derived multilineage progenitor cells (hADMPCs) in lowering serum total cholesterol in the homozygous Watanabe heritable hyperlipidemic (WHHL) rabbits, an animal model of homozygous FH. Here we demonstrate that pravastatin, an HMG-CoA reductase inhibitor, augmented the cholesterol-lowering effect of transplanted hADMPCs and enhanced LDL clearance in homozygous WHHL rabbit. The results suggest the potential beneficial effects of in situ stem cell therapy in concert with appropriately selected pharmaceutical agents, in regenerative medicine.
UR - http://www.scopus.com/inward/record.url?scp=80051798604&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80051798604&partnerID=8YFLogxK
U2 - 10.1016/j.bbrc.2011.07.035
DO - 10.1016/j.bbrc.2011.07.035
M3 - Article
C2 - 21806964
AN - SCOPUS:80051798604
SN - 0006-291X
VL - 412
SP - 50
EP - 54
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
IS - 1
ER -
